.jpeg)
2026-05-13 03:19:49
This article dissects the standard duration, long-term risks, and应对 strategies of Pretomanid (core component of BPaL regimen) for drug-resistant TB, highlighting the dangers of exceeding the recommended timeline and offering specialized guidance for patients who have used Pretomanid for three years.
2026-05-12 07:29:57
The SKYSCRAPER-02C study focuses on Chinese patients with extensive-stage small cell lung cancer (ES-SCLC), comparing the efficacy and safety of tiragolumab combination therapy versus standard treatment. Results demonstrate numerically improved PFS and OS with the combination, along with biomarker insights for personalized treatment.
2026-05-12 07:24:42
Research uncovers that lysophosphatidylcholine acyltransferase 3 (LPCAT3) plays a pivotal role in the progression of metabolic dysfunction-associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). Its deficiency promotes mitochondrial dysfunction and tumor formation, while overexpression reverses pathological processes, offering a novel therapeutic target.
2026-05-12 03:08:03
Tucatinib, an oral TKI developed by Seagen, selectively targets HER2 to inhibit cancer cell growth. Approved by FDA in 2020 for advanced HER2+ breast cancer (including brain metastases) and expanded to RAS-wildtype HER2+ CRC in 2023. This treatment, combined with trastuzumab and capecitabine, significantly prolongs survival and improves outcomes. This article details indications, dosing, precautions, and safety profiles for informed clinical use.
2026-05-12 02:17:51
Venetoclax, a BCL-2 inhibitor, demonstrates remarkable efficacy in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML). However, its potency necessitates stringent safety protocols, particularly in managing tumor lysis syndrome (TLS), neutropenia, infections, and pregnancy risks. This article unpacks monitoring strategies and risk mitigation practices from global clinical guidelines to optimize treatment outcomes.
2026-05-11 02:36:52
Pralsetinib, a highly selective RET inhibitor, is revolutionizing treatment for RET fusion-positive NSCLC and MTC. This article delves into its mechanism, clinical data, administration guidelines, and global accessibility, offering essential insights for patients and clinicians.
2026-05-06 03:26:04
Benralizumab (Fasenra) is generally safe for severe eosinophilic asthma, but potential risks exist. This guide covers common side effects (headache, sore throat), hypersensitivity, infection risks, and rare severe reactions, providing actionable strategies for patients and clinicians.
2026-05-06 03:15:20
Lemborexant, a novel insomnia medication, targets the orexin system to regulate sleep-wake cycles. Clinically proven to improve sleep onset and maintenance, it offers lower residual effects and dependency risks than traditional drugs, providing a safer alternative for adult insomnia patients.
2026-04-30 04:30:10
This article details the latest progress of AstraZeneca's Breztri Aerosphere, which received US FDA approval on April 28, 2026, for the maintenance treatment of asthma in patients aged 12 years and older. It analyzes its mechanism of action as the world's first single-inhaler triple therapy, key Phase III KALOS and LOGOS trial data, clinical value, and global regulatory status.
2026-04-30 04:24:41
This article provides a comprehensive interpretation of the core data from the international Phase III TROPION-Breast02 trial, comparing the efficacy, safety, and patient-reported outcomes of datopotamab deruxtecan versus chemotherapy as first-line treatment for advanced triple-negative breast cancer ineligible for immunotherapy, and discussing its clinical positioning, study limitations, and impact on the treatment landscape.
2026-04-30 04:14:23
This article details the mechanism of action, precise indications, eligible patient populations, and clinical value of elacestrant, analyzing its unique advantages and application boundaries in the treatment of endocrine-resistant hormone receptor-positive breast cancer.
2026-04-30 04:02:14
This article comprehensively reviews the latest research progress of vibegron in 2026, covering its core efficacy verification in overactive bladder (OAB), long-term safety evaluation, and expanded application in male patients with concomitant benign prostatic hyperplasia, analyzing key clinical trial data and clinical value.
